Vancomycin Heteroresistance and Survival in MRSA Bloodstream Infections
Author Information
Author(s): Sebastian van Hal, Mark Jones, Iain B. Gosbell, David L. Paterson
Primary Institution: Department of Microbiology and Infectious Diseases, Sydney South West Pathology Service – Liverpool Hospital
Hypothesis
Is there a mortality difference between hVISA and VSSA bloodstream infections?
Conclusion
hVISA in ST239 MRSA is associated with reduced mortality compared to VSSA.
Supporting Evidence
- hVISA was associated with chronic renal failure and previous vancomycin usage.
- Patients with hVISA had a significantly lower 30-day mortality rate compared to those with VSSA.
- Independent predictors of mortality included age and presence of multiple co-morbidities.
Takeaway
This study found that patients with a specific type of bacteria called hVISA are less likely to die from infections than those with a different type called VSSA.
Methodology
The study reviewed MRSA bloodstream infection episodes from 1996 to 2008, analyzing patient demographics, treatment, and mortality.
Potential Biases
Clinicians were unaware of hVISA status, which may have influenced treatment decisions.
Limitations
Data was gathered retrospectively, and the sample size for hVISA was relatively small.
Participant Demographics
The study included adult patients with MRSA bloodstream infections, with a median age of 60 years.
Statistical Information
P-Value
p=0.003
Confidence Interval
95% CI 0.09–0.83
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website